午夜福利在线播放,91色国产一区二区,亚洲欧美日韩电影,另类久久

產(chǎn)品展示 / products 您的位置:網(wǎng)站首頁 > 產(chǎn)品展示 > 細胞庫 > 細胞系 > 人乳腺癌細胞MCF-7
產(chǎn)品分類

Product category

相關文章

Related articles

人乳腺癌細胞MCF-7

人乳腺癌細胞MCF-7

簡要描述:青旗(上海)生物技術發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,逐步發(fā)展成為以生物技術為主的研發(fā)、生產(chǎn)、培訓為一體的綜合化產(chǎn)業(yè)平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細胞、細胞系、ELISA試劑盒、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務。我們秉承對用戶負責的態(tài)度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫(yī)學科研用戶提供更優(yōu)質的服務!

更新時間:2021-05-26

廠商性質:生產(chǎn)廠家

瀏覽次數(shù):363

詳情介紹
品牌其他品牌貨號BFN607200603
規(guī)格T25培養(yǎng)瓶x1 1.5ml凍存管x2供貨周期現(xiàn)貨
主要用途僅供科研應用領域醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細胞名稱

人乳腺癌細MCF-7

img1

貨物編碼

BFN607200603

產(chǎn)品規(guī)格

T25培養(yǎng)x1

1.5ml凍存x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研用途               1類

 

培養(yǎng)體系

DMEM高糖培養(yǎng)+20%FBS+1%三抗

培養(yǎng)溫度

37

二氧化碳濃度

5%

簡介

人乳腺癌細MCF-7細胞是從一69歲的白人女性乳腺癌患者的胸腔積液中分離建立的。該細胞保留了多個分化乳腺上皮的特性,包括:能通過胞質雌激素受體加工雌二醇并能形成隆突結構domes);該細胞表WNT7B癌基因;TNF-α可以抑MCF-7細胞的生長;抗雌激素處理能調節(jié)細胞胰島素樣生長因子結合蛋白IGFBP)的分泌。人乳腺癌細MCF-7細胞引種ATCC HIB-22。

注釋

Group: Space-flown cell line (cellonaut).

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: ENCODE project common cell types; tier 2.

Part of: JFCR39 cancer cell line panel.

Part of: JFCR45 cancer cell line panel.

Part of: GrayJW Breast Cancer Cell Line Panel.

Part of: ICBP43 breast cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Registration: Chiron Master Culture Collection; CMCC 10377 (CMCC #10377).

Doubling time: 1.8 days (PubMed=9671407); 80 hours (PubMed=25984343); 31.2 hours (PubMed=22628656); 25.4 hours (NCI-DTP); ~50 hours, with a range of 30-72 hours (DSMZ); ~38 hours (PBCF); 56.47 hours 

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: Glycoproteome analysis by proteomics.

Omics: H3K27ac ChIP-seq epigenome analysis.

Omics: H3K27me3 ChIP-seq epigenome analysis.

Omics: H3K36me3 ChIP-seq epigenome analysis.

Omics: H3K4me3 ChIP-seq epigenome analysis.

Omics: H3K9me3 ChIP-seq epigenome analysis.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: miRNA expression profiling.

Omics: Myristoylated proteins analysis by proteomics.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Omics: Virome analysis using proteomics.

Anecdotal: This is the first hormone-responsive breast cancer cell line to have been established.

Anecdotal: Helen Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun (Sister Catherine Frances) at the Immaculate Heart of Mary Convent in Monroe, Michigan.

Anecdotal: Have been flown in space on Foton-12 to study cytoskeleton architecture in microgravity (PubMed=11292682; PubMed=15002416).

Misspelling: MFC-7; Occasionally.

STR信息

AmelogeninX;CSF1PO10;D13S31711;D16S53911,12D18S5114;D19S43313,14D21S1130;D2S133821,23;D3S135816;D5S8181112;D7S8208,9D8S117910,14FGA23,24,25TH016;TPOX912;vWA14,15

參考文獻

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470

Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.

Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.

J. Proteome Res. 16:1391-1400(2017)

 

PubMed=28601559; DOI=10.1016/j.cels.2017.05.009

Bekker-Jensen D.B., Kelstrup C.D., Batth T.S., Larsen S.C., Haldrup C., Bramsen J.B., Sorensen K.D., Hoyer S., Orntoft T.F., Andersen C.L., Nielsen M.L., Olsen J.V.

An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.

Cell Syst. 4:587-599.e4(2017)

 

PubMed=28889351; DOI=10.1007/s10549-017-4496-x

Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Breast Cancer Res. Treat. 167:289-301(2018)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

驗收細胞注意事 

1、收到人乳腺癌細MCF-7細胞,請查看瓶子是否有破裂,培養(yǎng)基是否漏出,是否渾濁,如有請盡快聯(lián)系。 

2、收到人乳腺癌細MCF-7 ,如包裝完好,請在顯微鏡下觀察細胞,由于運輸過程中的問題,細胞培養(yǎng)瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現(xiàn)細胞懸浮的情況,出現(xiàn)此狀態(tài)時,請不要打開細胞培養(yǎng)瓶,應立即將培養(yǎng)瓶置于細胞培養(yǎng)箱里靜 3-5 小時左右,讓細胞先穩(wěn)定下,再于顯微鏡下觀察,此時多數(shù)細胞會重新貼附于瓶壁。如細胞仍不能貼壁,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。 

3、收到人乳腺癌細MCF-7細胞后,請鏡下觀察細胞,用恰當方式處理細胞。若懸浮的細胞較多,請離心收集細胞,接種到一個新的培養(yǎng)瓶中。棄掉原液,使用新鮮配制的培養(yǎng)基,使用進口胎牛血清。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養(yǎng)。若細胞迏 80% ,血清濃度還是 10 

4、收到人乳腺癌細MCF-7細胞時如無異常情 ,請在顯微鏡下觀察細胞密度,如為貼壁細胞,未超80%匯合度時,將培養(yǎng)瓶中培養(yǎng)基吸出,留 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng):超 80%匯合度時,請按細胞培養(yǎng)條件傳代培養(yǎng)。如為懸浮細胞,吸出培養(yǎng)液,1000 /分鐘離 3 分鐘,吸出上清,管底細胞用新鮮培養(yǎng)基懸浮細胞后移回培養(yǎng)瓶。 

5、將培養(yǎng)瓶置 37培養(yǎng)箱中培養(yǎng),蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需。 

6、24 小時后,細胞形態(tài)已恢復并貼滿瓶壁,即可傳代。(貼壁細胞)將培養(yǎng)瓶里的培養(yǎng)基倒去, 3-5ml(以能覆蓋細胞生長面為準PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細胞為準,一 1-3 分鐘,不超 5 分鐘??梢苑?/span>37培養(yǎng)箱消化。輕輕晃動瓶壁,見細胞脫落下來,加 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細胞,使之*脫落,然后將溶液吸入離心管內離心1000rpm/5min。棄上清,視細胞數(shù)量決定分瓶數(shù),一般一傳二,如細胞量多可一傳三,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,以具體細胞和經(jīng)驗為準。(懸浮細胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可。 

7、貼壁細 ,懸浮細胞。嚴格無菌操作。換液時,換新的細胞培養(yǎng)瓶和換新鮮的培養(yǎng)液,37,5%CO2 培養(yǎng)。

 

特別提醒 原瓶中培養(yǎng)基不宜繼續(xù)使用,請更換新鮮培養(yǎng)基培養(yǎng)。



留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數(shù)字),如:三加四=7

聯(lián)